Stock NRX NUREXONE BIOLOGIC INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NurExone Biologic Inc.

Equities

NRX

CA67059R1091

Delayed Toronto S.E.
Other stock markets
 02:12:30 2024-05-15 pm EDT 		5-day change 1st Jan Change
0.51 CAD -1.92% Intraday chart for NurExone Biologic Inc. -13.56% +72.88%
Apr. 25 NurExone Biologic Announces OTCQB Listing And DTC Eligibility MT
Apr. 02 NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NurExone Biologic Announces OTCQB Listing And DTC Eligibility
MT
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
AQ
NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
AQ
NurExone Biologic Building a Research and Development Facility in Israel
MT
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
AQ
NurExone Biologic Inc. Establishes Research and Development Facility in Haifa, Israel
CI
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
AQ
NurExone’s Intellectual Property Portfolio Expands
AQ
NurExone Biologic Inc. Expands Intellectual Property Portfolio
CI
NurExone Launches Licensing Efforts For ExoTherapy Platform
MT
NurExone Launches Licensing Efforts for ExoTherapy Platform
AQ
NurExone Biologic Inc. Launches Licensing Efforts for ExoTherapy Platform
CI
NurExone Biologic Provides Operations Update
MT
NurExone Biologic Posts Q1 Net Loss
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRX Stock
  4. News NurExone Biologic Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW